Shepherd Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,736 shares of the biopharmaceutical company's stock, valued at approximately $752,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Research Global Investors increased its position in shares of Alnylam Pharmaceuticals by 7.3% in the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company's stock valued at $470,018,000 after buying an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock worth $550,837,000 after acquiring an additional 201,784 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 92.5% during the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company's stock valued at $65,862,000 after purchasing an additional 130,482 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at approximately $18,886,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $29,111,000. 92.97% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Price Performance
ALNY traded up $7.32 during trading on Friday, hitting $273.91. The stock had a trading volume of 866,294 shares, compared to its average volume of 871,240. The company has a 50 day moving average price of $274.59 and a 200-day moving average price of $224.99. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm has a market cap of $35.16 billion, a price-to-earnings ratio of -104.55 and a beta of 0.39.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same quarter last year, the firm posted ($2.21) earnings per share. The company's quarterly revenue was up 107.0% on a year-over-year basis. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.59 EPS for the current fiscal year.
Insider Buying and Selling at Alnylam Pharmaceuticals
In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the firm's stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the sale, the director now owns 136 shares of the company's stock, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.
Analyst Ratings Changes
Several analysts have commented on ALNY shares. Scotiabank raised their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a "sector outperform" rating in a report on Friday. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research note on Monday, August 26th. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research note on Friday. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the company from $198.00 to $370.00 in a research note on Friday, August 16th. Finally, Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Six investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $294.50.
Read Our Latest Stock Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Company Profile
(
Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
